Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

NCT ID: NCT00004998

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-11-30

Brief Summary

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

Detailed Description

[Note: As of 2/28/2001, due to toxicity studies and concerns for safety, sites were notified that they need to discontinue patients from the capravirine/placebo arms and continue patients with their background therapies or switch patients to new therapies, as deemed appropriate by the investigators.] Patients are randomized to receive one of two doses of AG1549 plus Viracept (nelfinavir) plus Combivir (zidovudine/lamivudine). Patients remain on their assigned therapy for 48 weeks, with a follow-up visit at 28 to 35 days after the last dose of study medication. Blood samples are taken regularly to quantify HIV-1 RNA, CD4 and CD8 counts, peripheral blood mononuclear cells (PBMC), AG1549, Viracept, and M8 plasma concentrations. Physical exams, safety assessments, and other tests are also done throughout the study. On Day 8 and at the end of Week 48, pharmacokinetic samples are collected at 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, and 12.0 hours postdose. At the end of Weeks 4, 8, 16, 24, and 36, pharmacokinetic samples are taken prior to dosing and between 2 to 4 hours post-dose.

Conditions

HIV Infections

Keywords

Drug Therapy, Combination; Zidovudine; HIV Protease Inhibitors; Lamivudine; Reverse Transcriptase Inhibitors; Anti-HIV Agents; Nelfinavir; Combivir

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Lamivudine/Zidovudine

Intervention Type: DRUG

Capravirine

Intervention Type: DRUG

Nelfinavir mesylate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients may be eligible if they:

• Are HIV-positive.
• Are at least 18 years old.
• Have a CD4 cell count of more than 50 cells/mm3.
• Have an HIV level of more than 5000 copies/ml.

Exclusion Criteria

Patients will not be eligible if they:

• Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
• Have taken an experimental drug within 28 days of study entry.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Agouron Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Locations

Clin Research of West Florida

Clearwater, Florida, United States

Community Health Care

Fort Lauderdale, Florida, United States

South Shore Hosp

Miami, Florida, United States

Infectious Diseases Associates

Sarasota, Florida, United States

AIDS Research Consortium of Atlanta

Atlanta, Georgia, United States

Beth Israel Deaconess Med Ctr

Boston, Massachusetts, United States

Catholic Med Ctr

Jamaica, New York, United States

Liberty Medical

New York, New York, United States

Anderson Clinical Research

Pittsburgh, Pennsylvania, United States

Immunity Care and Research Inc

Santo Domingo, , Dominican Republic

Countries

United States; Dominican Republic

Other Identifiers

AG1549-503

Identifier Type: -

Identifier Source: secondary_id

286B

Identifier Type: -

Identifier Source: org_study_id